LOGIN  |  REGISTER

908 Devices to Participate in Upcoming Investor Conferences

October 31, 2023 | Last Trade: US$5.62 0.03 -0.53

BOSTON / Oct 31, 2023 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences.

  • 53rd Annual Baird Industrial Conference
    In-person presentation only on Wednesday, November 8th at 10:35 a.m. Pacific Time / 1:35 a.m. Eastern Time
  • Stifel Healthcare Conference 2023
    Fireside chat on Tuesday, November 14th at 5 a.m. Pacific Time / 8 a.m. Eastern Time
  • 25th Annual Stephens Investment Conference
    Fireside chat on Wednesday, November 15 at 6 a.m. Pacific Time / 9 a.m. Eastern Time

Interested parties may access a live and archived webcast of these sessions on the “Investors” section of the company website at: www.908devices.com.

About 908 Devices

908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB